Literature DB >> 29633980

Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.

Clément Deltombe1, Claire Garandeau1, Karine Renaudin2, Maryvonne Hourmant1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29633980     DOI： 10.1097/TP.0000000000001861

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  11 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

2.  Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.

Authors:  Merve Hasanov; Sergej N Konoplev; Cristhiam M Rojas Hernandez
Journal:  Blood Adv       Date:  2018-08-14

3.  Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.

Authors:  Sandhya Manohar; Charat Thongprayoon; Wisit Cheungpasitporn; Svetomir N Markovic; Sandra M Herrmann
Journal:  Kidney Int Rep       Date:  2019-12-07

Review 4.  The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Authors:  Rossana Franzin; Giuseppe Stefano Netti; Federica Spadaccino; Camillo Porta; Loreto Gesualdo; Giovanni Stallone; Giuseppe Castellano; Elena Ranieri
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

5.  Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants.

Authors:  Young Jun Shim; Raneem Khedraki; Jayeeta Dhar; Ran Fan; Nina Dvorina; Anna Valujskikh; Robert L Fairchild; William M Baldwin
Journal:  Kidney Int       Date:  2020-04-25       Impact factor: 10.612

6.  Gene Expression Profiling in Kidney Transplants with Immune Checkpoint Inhibitor-Associated Adverse Events.

Authors:  Benjamin A Adam; Naoka Murakami; Graeme Reid; Katie Du; Ruqaya Jasim; Christie L Boils; Lihong Bu; Peter D Hill; Allan G Murray; Karine Renaudin; Candice Roufosse; Astrid Weins; Kevin Wen; Leonardo V Riella; Michael Mengel
Journal:  Clin J Am Soc Nephrol       Date:  2021-07-09       Impact factor: 10.614

7.  Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.

Authors:  Yuriko Ueki; Manabu Suzuki; Yuriko Horikawa; Hiromu Watanabe; Yoh Yamaguchi; Chie Morita; Akinari Tsukada; Hiroshi Takumida; Yusaku Kusaba; Takashi Katsuno; Yoshie Tsujimoto; Keita Sakamoto; Masao Hashimoto; Junko Terada; Satoru Ishii; Jin Takasaki; Go Naka; Motoyasu Iikura; Shinyu Izumi; Yuichiro Takeda; Masayuki Hojo; Haruhito Sugiyama
Journal:  Thorac Cancer       Date:  2020-08-07       Impact factor: 3.500

Review 8.  Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?

Authors:  Hung-Chih Lai; Ji-Fan Lin; Thomas I S Hwang; Ya-Fang Liu; An-Hang Yang; Chung-Kuan Wu
Journal:  Int J Mol Sci       Date:  2019-05-03       Impact factor: 5.923

Review 9.  Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.

Authors:  Juwhan Choi; Sung Yong Lee
Journal:  Immune Netw       Date:  2020-02-17       Impact factor: 6.303

10.  Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Nabil E Omar; Kareem A El-Fass; Abdelrahman I Abushouk; Noha Elbaghdady; Abd Elmonem M Barakat; Ahmed E Noreldin; Dina Johar; Mohamed Yassin; Anas Hamad; Shereen Elazzazy; Said Dermime
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.